| 99.64 -1.55 (-1.53%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 119.06  |
1-year : | 125.5 |
| Resists | First : | 101.93 |
Second : | 107.44 |
| Pivot price | 101.16  |
|||
| Supports | First : | 93.01 |
Second : | 77.39 |
| MAs | MA(5) : | 100.99 |
MA(20) : | 100.09 |
| MA(100) : | 82.89 |
MA(250) : | 56.61 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 46.4 |
D(3) : | 51.8 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 124.48 | Low : | 29.17 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RVMD ] has closed above bottom band by 32.6%. Bollinger Bands are 58% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 101.35 - 101.91 | 101.91 - 102.37 |
| Low: | 96.46 - 97.25 | 97.25 - 97.9 |
| Close: | 98.46 - 99.65 | 99.65 - 100.61 |
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Thu, 05 Mar 2026
This One Data Readout Could Make Or Break Revolution Medicines (NASDAQ:RVMD) - Seeking Alpha
Wed, 04 Mar 2026
Handelsbanken Fonder AB Grows Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Tue, 03 Mar 2026
Revolution Medicines director Goldsmith sells shares worth $3.64 million - Investing.com
Tue, 03 Mar 2026
Revolution Medicines (RVMD) awards options and shares to officer Xiaolin Wang - Stock Titan
Tue, 03 Mar 2026
Revolution Medicines (RVMD) officer receives new stock options and share grant - Stock Titan
Tue, 03 Mar 2026
Revolution Medicines, Inc. $RVMD Shares Purchased by Legato Capital Management LLC - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 193 (M) |
| Shares Float | 174 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 104.9 (%) |
| Shares Short | 13,070 (K) |
| Shares Short P.Month | 15,310 (K) |
| EPS | -5.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.42 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.3 % |
| Return on Equity (ttm) | -60.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -4.56 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -762 (M) |
| Levered Free Cash Flow | -438 (M) |
| PE Ratio | -19.2 |
| PEG Ratio | 0 |
| Price to Book value | 11.83 |
| Price to Sales | 0 |
| Price to Cash Flow | -25.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|